CSPC Pharma stock gains 1.47 percent as eight trials head to ESMO 2026
Published on 10/06/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
CSPC Pharma stock (ISIN HK1093012172) was last at HKD 10.00 on HKEX on October 6, 2026 at 4:08 p.m. HKT, up 1.47 percent from the prior close. The move followed a company announcement that eight clinical trial updates will be presented at the 2026 European Society for Medical Oncology Congress. CSPC Pharma listed the announcement among its latest investor-relations releases dated October 5, 2026.
Eight trials sharpen the pipeline story
The ESMO program gives the stock a near-term clinical focus, with oncology data standing alongside CSPC's broader pipeline of nervous-system, anti-tumor, cardiovascular and metabolic medicines. The company profile describes finished drugs, bulk products and functional food as its main business lines, while the pipeline spans domestic and overseas markets.
The event matters because it puts several development programs in front of an international oncology audience at the same time. Futu reported on October 6, 2026 that the eight updates would be presented at the annual congress, including the company's 01093 listing.
Interim profit growth raises the bar
CSPC's 2026 interim results provide the financial counterweight to the pipeline news. According to CSPC Pharma, revenue for the six months of 2026 reached RMB 18,594 million, an increase of 40.1 percent from the comparable period.
Reported profit attributable to shareholders rose 139.2 percent to RMB 6,094 million, while underlying profit climbed 165.8 percent to RMB 6,164 million. Basic earnings per share increased 139.8 percent to RMB 0.5345, making execution in the commercial business as important as the clinical milestones ahead.
Consensus target stays above HKD 10
MarketScreener showed a BUY consensus from 24 analysts, with an average target of HKD 12.54 and a published spread of 29.12 percent above its then last close of HKD 9.71. Against the October 6 price of HKD 10.00, the average target lies 25.4 percent above the market level.
CSPC Pharma's market capitalization stood at HKD 114.1 billion on October 6, 2026. The 52-week range was HKD 6.53 to HKD 10.96, and volume reached 36,502,954 shares, placing the latest price 8.76 percent below the 52-week high.
Stock gains on October 6
CSPC Pharma stock was last at HKD 10.00 on HKEX on October 6, 2026 at 4:08 p.m. HKT, with an intraday range of HKD 9.86 to HKD 10.11.
CSPC Pharma stock facts
- Company: CSPC Pharmaceutical Group Limited
- ISIN: HK1093012172
- Ticker: 1093
- Trading venue: HKEX
- Price (as of October 6, 2026, 4:08 p.m. HKT): HKD 10.00
- Market capitalization: HKD 114.1 billion (as of October 6, 2026)
- 52-week range: HKD 6.53-10.96 (as of October 6, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: Hang Seng Index
Upcoming dates for CSPC Pharma stock
- October 20, 2026: Ex-dividend date for HKD 0.18
